C6K0
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
C6K0 (C6K0) - Total Liabilities
Latest total liabilities as of September 2025: €33.55 Million EUR
Based on the latest financial reports, C6K0 (C6K0) has total liabilities worth €33.55 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
C6K0 - Total Liabilities Trend (2021–2024)
This chart illustrates how C6K0's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
C6K0 Competitors by Total Liabilities
The table below lists competitors of C6K0 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dogu Aras Enerji Yatirimlari AS
IS:ARASE
|
Turkey | TL8.69 Billion |
|
AVY Precision Technology
TWO:5392
|
Taiwan | NT$6.79 Billion |
|
Suzhou Longjie Special Fiber Co Ltd
SHG:603332
|
China | CN¥226.45 Million |
|
Owens & Minor Inc
NYSE:OMI
|
USA | $4.47 Billion |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
Korea | ₩137.93 Billion |
|
Concrete Pumping Holdings Class A
NASDAQ:BBCP
|
USA | $589.75 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down C6K0's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how C6K0's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for C6K0 (2021–2024)
The table below shows the annual total liabilities of C6K0 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €17.70 Million | +29.30% |
| 2023-12-31 | €13.69 Million | -69.09% |
| 2022-12-31 | €44.28 Million | -22.49% |
| 2021-12-31 | €57.13 Million | -- |